Poland· PL-100327407
Imbruvica
A ibrutinib product containing ibrutinibum, registered in Poland by Janssen-Cilag International N.V.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Ibrutinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EL01 (ibrutinib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Ibrutinib · ATC L01EL01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ibrutinib costs, country by country.
Normalised to the WHO defined daily dose (0.42 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ibrutinib · price per daily dose (0.42 g)
USD · FX 28 Sept 2026
- CH Switzerland$193.73
The record
At a glance
URPL (Poland)- Active substance
- Ibrutinibum
- Manufacturer
- Janssen-Cilag International N.V.
- Country
- Poland (PL)
- ATC code
- L01EL01
- ATC class
- Ibrutinib
- Defined daily dose
- 0.42 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991195137
- gtin05909991195144
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
370 interactions on record for ibrutinib.
Graded by severity as the source publishes them — 189 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ibrutinib · interactions on record
370 records
- 189 severe
- 177 moderate
- 4 minor
Most severe, free to view
- AprepitantA04AD12severe
- LinseedA06AC05severe
- LonafarnibA16AX20severe
- DicoumarolB01AA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ibrutinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandImbruvicaParanova Oy
- SpainIMBRUVICA 140 MG CAPSULAS DURASJanssen-Cilag International N.V
- CzechiaIMBRUVICAJanssen-Cilag International N.V., Beerse
- United KingdomImbruvica 140mg capsulesJanssen-Cilag Ltd
- IrelandIMBRUVICA 140 mg hard capsulesJanssen-Cilag International NV
- IcelandIMBRUVICAJanssen-Cilag International NV*
- NetherlandsIMBRUVICA 140 mg, harde capsulesJanssen-Cilag International NV
- SwedenIMBRUVICA 140 mg Kapsel, hårdJanssen-Cilag International NV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imbruvica
- Liechtenstein · Imbruvica
- Norway · Imbruvica
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/83fbc6af-d1d5-40b3-8e72-44e7f7230303 GET /v1/drugs/83fbc6af-d1d5-40b3-8e72-44e7f7230303?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Kapsułki twarde",
"source": "urpl",
"strength": "140 mg",
"packaging": "05909991195137 ¦ Rpz ¦ EU/1/14/945/001 ¦ 104792\n90 kaps.\n05909991195144 ¦ Rpz ¦ EU/1/14/945/002 ¦ 104793\n120 kaps.",
"substance": "Ibrutinibum 140 mg",
"common_name": "Ibrutinibum",
"pl_product_id": "100327407",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ibrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.